ATOSClinical Trials•prnewswire•August 20, 2025 at 12:30 PM

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

Sentiment:Neutral (45)

Summary

Monotherapy Phase 2 study designed with FDA input; IND expected in Q4 2025 Topline results anticipated in 2026 Positions Atossa for transition into registrational Phase 3 development SEATTLE, Aug. 20, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the...

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 20, 2025 by prnewswire